Skip to content

Cannabis for addiction: all studies

Page 8 of 9: studies 71 to 80 of 88, newest first. Back to the cannabis for addiction overview

Research

Neurological soft signs in non-psychotic patients with cannabis dependence.

Addiction Biology March 2013 Alain Dervaux, Marie-Chantal Bourdel, Xavier Laqueille et al.

Psychomotor performance has consistently been found to be altered in chronic cannabis users. Neurological soft signs (NSS) reflect neurological dysfunction involving integrative networks, especially those involving the cerebellum, where cannabinoid receptors are particularly concentrated. Our objective was to study, for the first time, NSS in a group of patients with cannabis dependence...

Neural Correlates of the Severity of Cocaine, Heroin, Alcohol, MDMA and Cannabis Use in Polysubstance Abusers: A Resting-PET Brain Metabolism Study

PLoS One June 29, 2012 Laura Moreno-López, Emmanuel A. Stamatakis, María José Fernández-serrano et al. 73 citations

INTRODUCTION: Functional imaging studies of addiction following protracted abstinence have not been systematically conducted to look at the associations between severity of use of different drugs and brain dysfunction. Findings from such studies may be relevant to implement specific interventions for treatment. The aim of this study was to examine the association between resting-state regional...

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.

Drug and Alcohol Dependence July 1, 2011 Frances R. Levin, John J Mariani, Daniel J Brooks et al.

Cannabis dependence is a substantial public health problem. Behavioral treatments have shown promise, but there are no effective medications for cannabis dependence. The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, in treating cannabis...

Marijuana dependence: not just smoke and mirrors.

ILAR Journal 2011 Divya Ramesh, Joel E Schlosburg, Jason M Wiebelhaus et al.

Marijuana (Cannabis sativa) is the most commonly used illicit drug worldwide as well as in the Unites States. Prolonged use of marijuana or repeated administration of its primary psychoactive constituent, Δ9-tetrahydrocannabinol (THC), can lead to physical dependence in humans and laboratory animals. The changes that occur with repeated cannabis use include alterations in behavioral,...

Are the effects of cannabis dependence on glucose metabolism similar to schizophrenia? An FDG PET understanding.

Indian Journal of Psychiatry January 2011 Shubhangi R Parkar, Seethalakshmi Ramanathan, Narendra Nair et al.

Cannabis has been associated with transient psychotic states; however, the causal relationship between cannabis and schizophrenia continues to remain a matter of debate. Epidemiological and some biological studies hint at cannabis being an independent risk factor for schizophrenia; this has not been definitively proved. We aimed to understand the patterns of glucose uptake in important brain...

DOI: 10.4103/0019-5545.75552 (opens in new tab) Full text (opens in new tab) Cannabis dependence Fdg PET Interregional relationships Schizophrenia

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Journal of Substance Use July 30, 2010 R. L. Carhart-Harris, D. J. Nutt 108 citations

This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were submitted. Users were asked to comment on the acute and prolonged effects of different drugs and to provide more specific information on how particular drugs have harmed and/or helped them. Subjects reported relatively less harm associated with the...

Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence.

Addiction Biology July 2010 Saturnino Spiga, Alessandra Lintas, Michele Migliore et al.

Cannabinoid withdrawal produces a hypofunction of mesencephalic dopamine neurons that impinge upon medium spiny neurons (MSN) of the forebrain. After chronic treatment with two structurally different cannabinoid agonists, Delta(9)-tetrahydrocannabinol and CP55 940 (CP) rats were withdrawn spontaneously and pharmacologically with the CB1 antagonist SR141716A (SR). In these two conditions,...

Assessment of addiction severity among ritual users of ayahuasca

Drug and Alcohol Dependence June 17, 2010 Josep María Fábregas, Débora González, Sabela Fondevila et al. 228 citations

Ayahuasca is a psychoactive beverage used for magico-religious purposes in the Amazon. Recently, Brazilian syncretic churches have helped spread the ritual use of ayahuasca abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine-containing tea may lead to the medical and psychosocial problems typically associated with drugs of abuse. Here we assess potential drug...

Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats.

Neuropsychopharmacology October 2009 Lydie J Morel, Bruno Giros, Valérie Daugé

Maternal deprivation in rats specifically leads to a vulnerability to opiate dependence. However, the impact of cannabis exposure during adolescence on this opiate vulnerability has not been investigated. Chronic dronabinol (natural delta-9 tetrahydrocannabinol, THC) exposure during postnatal days 35-49 was made in maternal deprived (D) or non-deprived (animal facility rearing, AFR) rats. The...

The endocannabinoid system as a target for the treatment of cannabis dependence

Neuropharmacology July 19, 2008 Jason R. Clapper, Regina A. Mangieri, Daniele Piomelli

The endocannabinoid system modulates neurotransmission at inhibitory and excitatory synapses in brain regions relevant to the regulation of pain, emotion, motivation, and cognition. This signaling system is engaged by the active component of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2)...